Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance Find Stocks Now
Close

AnaptysBio Inc (ANAB)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow AnaptysBio's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
19.66 -0.21    -1.06%
22/04 - Closed. Currency in USD ( Disclaimer )
After Hours
19.38
-0.28
-1.42%
19:47:54 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 139,694
  • Bid/Ask: 15.00 / 31.98
  • Day's Range: 19.60 - 20.26
AnaptysBio 19.66 -0.21 -1.06%

AnaptysBio Inc Company Profile

 
Get an in-depth profile of AnaptysBio Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

96

Equity Type

ORD

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Contact Information

Address 10770 Wateridge Circle Suite 210
San Diego, 92121-5801
United States
Phone 858 362 6295
Fax 858 362 6296

Top Executives

Name Age Since Title
Laura J. Hamill 57 2019 Independent Director
John P. Schmid 59 2015 Independent Director
Hollings C. Renton 75 2015 Lead Independent Director
Dennis M. Fenton 70 2018 Independent Director
Daniel R. Faga 43 2021 President, CEO & Director
W. Michael Gallatin 69 - Member of Scientific Advisory Board
J. Anthony Ware 70 2017 Independent Director
Oleg Nodelman 46 2021 Independent Director
Magda Marquet 64 2021 Independent Director
Luisa Salter-Cid 59 - Member of Scientific Advisory Board
Christopher Hunter - - Member of Scientific Advisory Board
John G. Monroe - - Member of Scientific Advisory Board
Rita I. Jain 60 2023 Independent Director
Dolca Thomas 52 2023 Member of Scientific Advisory Board
John A. Orwin 58 2023 Chairman of the Board
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ANAB Comments

Write your thoughts about AnaptysBio Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
pratik lalka
pratik lalka Oct 12, 2022 10:05AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Yael Aviv
Yael Aviv Dec 28, 2020 7:54AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
HC Wainwright dropped their price objective on shares of Abeona Therapeutics from $11.00 to $8.00 and set a "buy" rating on the stock in a research note on Wednesday, November 25th.
Elena Shevtsova
Elena Shevtsova Oct 15, 2020 8:49PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Hi, I’m the second! Thinking to enter in this paper carefully.
MoneyManager MoneyManager
Money2Manage4U Oct 15, 2020 8:49PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
MY sweet Elena please do not do this . where are you from ? I am from Greece . You ? if you want to enter go to Vonage VG.
MoneyManager MoneyManager
Money2Manage4U Oct 15, 2020 8:49PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
you had right but now is late try to Vonage VG you will remember me if you will earn money come to Greece to visit me i am a Stock Consultant . Lefteris from Greece.
lance thompson
lance thompson Oct 10, 2017 10:07PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I'm the first to comment! Lucky me!
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email